CURRENT TOPICS IN NUTRACEUTICAL RESEARCH Vol. 11, No. 1/2, pp. 9-14, 2013
ISSN 1540-7535 print, Copyright © 2013 by New Century Health Publishers, LLC
www.newcenturyhealthpublishers.com
All rights of reproduction in any form reserved
These in-vitro studies on 13 different cancer cell lines conducted under the auspices of the Josephine Ford Cancer Center, Henry Ford Hospital, Detroit, MI proved that contrary to the NCI studies, “Cantron® has in-vitro anticancer activity as well as anticancer therapeutic potential.” Further study to determine any in vivo therapeutic effects in tumor bearing models need to be performed according to the research team. It should be pointed out that a difference between the exposure duration (5 days) and that of NCI (2 days) is likely the basis for the significant difference in Cantron® activity reported. These studies confirm that the developer of Cantron®, Jim Sheridan was correct in his assessment that the slower acting and less toxic Cantron material needed to be tested in a 5-7 day paradigm, not the paradigm designed for toxic chemotherapeutic agents that the NCI invariably uses in their studies.
Disclaimer: The FDA has not reviewed this article. This article is for information purposes only. Cantron is a dietary supplement with powerful antioxidant properties. No claims for the cure, prevention or mitigation of any disease are made or implied!
According to the Dietary Supplement Act of 1994, dietary supplement manufacturers and distributors may disseminate articles from peer-reviewed journals and from complete chapters in books which have information about their products if those articles and chapters are not part of the label. This article in fact is from a peer-reviewed journal. By clicking on the following link you understand that this article is offered for information purposes only, is not intended to be a part of the product label, and that no claims for the cure, prevention or mitigation of any disease are made or implied!
